NYSEMKT: OSTXOs Therapies Inc Stock
$1.60-0.01 (-0.62%)
Updated Aug 13, 2026
OSTX Price
$1.60
Fair Value Price
N/A
Market Cap
$71.26M
52 Week Low
$1.15
52 Week High
$2.57
P/E
-1.48x
P/B
-6.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.58
Operating Cash Flow
-$15M
Beta
1.05
Next Earnings
Aug 17, 2026
Ex-Dividend
N/A
Next Dividend
N/A
OSTX Overview
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OSTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OSTX
Ranked#453 of 464
Ranked#453 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $110.51 | A | |
| $10.90 | A |
Be the first to know about important OSTX news, forecast changes, insider trades & much more!
OSTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OSTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OSTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OSTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OSTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OSTX due diligence checks available for Premium users.
Valuation
OSTX fair value
Fair Value of OSTX stock based on Discounted Cash Flow (DCF)
Price
$1.60
Fair Value
$0.01
Overvalued by
17,246.03%
OSTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OSTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.48x
Industry
16.75x
Market
14.17x
OSTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.58x
Industry
5.71x
OSTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.4M
Profit Margin
0%
OSTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.3M
Liabilities
$17.1M
Debt to equity
-1.58
OSTX's short-term liabilities ($16.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OSTX's short-term assets ($917.55k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OSTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OSTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$0.0
Financing
$5.2M
OSTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OSTX vs Biotech Stocks
Os Therapies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.